And the germline beat (AML) goes on Comment

In this issue of Blood, Yang et al(1) report on the germline screening of 391 patients from the BEAT acute myeloid leukemia (AML) study, finding that 13.6% of patients unselected by family history have pathogenic or likely pathogenic variants of known cancer-predisposition genes.

Automated summary

In their study, Yang et al found that 13.6% of AML patients unselected by family history have pathogenic or likely pathogenic variants of known cancer-predisposition genes.